Viatris), as the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD) in 2019, William B. Feldman, MD, DPhil, MPH, an instructor in medicine at Brigham and ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score ...

In addition, the patents on several COPD medications have expired in recent years, opening the market to lower-priced generic drugs that your healthcare provider can prescribe instead. These ...

U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over a recent 15-year period, but a new study found that generic companies have only twice ...

In 2019, the U.S. Food and Drug Administration (FDA) approved the first generic maintenance inhaler for asthma and COPD. The inhaler, Wixela Inhub (fluticasone–salmeterol; Viatris), is a ...

The demand for inhalation and nasal spray generic drugs is growing as these medications provide affordable and effective treatment options for respiratory ailments like asthma, COPD, and allergies.

Medicare usually covers the cost of inhalers for people with asthma, COPD, or certain other conditions ... into four tiers based on their costs. Generic medications tend to cost less and occupy ...

About 70% of COPD patients struggle with flare-ups despite using inhalers, especially when eosinophil levels exceed this threshold. Nucala (generic name mepolizumab) works alongside inhalers.

Teva also is facing a legal challenge from Amneal Pharmaceuticals, which has sought to make a generic version of ... dozen patents for its asthma and COPD inhalers, according to confidential ...